8种药品被重点监控 两款利肺片11次“上榜”

Core Viewpoint - The Shanghai Pharmaceutical Procurement Center has announced a list of drugs that will be closely monitored due to exceeding the "yellow line" price threshold and not passing fairness assessments, with specific focus on eight drugs including Lipei Tablets and Huoxue Tongmai Capsules [1][2]. Group 1: Key Monitoring Drugs - Eight drugs have been identified for close monitoring, including Lipei Tablets produced by Chongqing Tianzhi Pharmaceutical Co., Ltd. and Sanpu Pharmaceutical Co., Ltd., and Huoxue Tongmai Capsules produced by the same companies [2][3]. - Lipei Tablets have consistently appeared on the monitoring list, making them a "full attendance" product, indicating ongoing scrutiny from regulatory bodies [3]. Group 2: Market Data and Sales - The market size for Lipei Tablets was approximately 12.5 billion yuan in 2023, indicating significant sales volume [3]. - The retail prices for Lipei Tablets are around 40 yuan per box for Sanpu Pharmaceutical's product and 35 yuan per box for Chongqing Tianzhi's product [3]. Group 3: Regulatory Framework - Since September 2018, Shanghai has implemented a public bidding procurement system for drugs, utilizing a "green line, yellow line, red line" pricing mechanism to monitor and regulate drug prices [5]. - The monitoring list serves as a reminder for medical institutions to negotiate prices based on market supply and demand, ensuring reasonable pricing while meeting clinical needs [6].